FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

O’Farrell M, Duke G, Crowley R, Buckley D, Martins EB, Bhattacharya D, Friedman SL, Kemble G. Sci Rep. 2022 Sep 19;12(1):15661. doi: 10.1038/s41598-022-19459-z.